Core Viewpoint - Frontera Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, aiming to provide innovative gene therapy solutions globally, particularly targeting ophthalmic and cardiovascular diseases [1] Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company founded in 2019, focusing on the development of innovative therapies [1] - The company has developed a differentiated pipeline of recombinant adeno-associated virus (trAAV) gene therapies with global best-in-class potential [1] Business Strategy - The company is dedicated to providing safe, effective, and affordable gene therapy solutions for patients worldwide [1] - Frontera Therapeutics has an international business layout, indicating a strategic approach to global market penetration [1]
新股消息 | Frontera Therapeutics递表港交所
智通财经网·2025-12-23 22:25